STRUCTURE SEARCH

ACCESS DB # _____

FOR OFFICIAL USE ONLY *PLEASE PRINT CLEARLY*

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: JANE ZARA Examiner # : 7752 Date: 11-30-07
Art Unit: 1635 Phone Number: 2-0765 Serial Number: 10/584,482
Location (Bldg/Room#): 2A59 (Mailbox #): 2C18 Results Format Preferred (circle): PAPER DISK
****

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: Method for Controlling SR Protein Phos...
Inventors (please provide full names): M. HAGIWARA et al.

Earliest Priority Date: 6-23-06

Search Topic:
Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only ***Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.***

Please Search the Structures of claims 16, 24, 26
(claims are attached)

Author Search

```
=> FILE HCAPLUS
FILE 'HCAPLUS' ENTERED AT 16:46:23 ON 03 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 3 Dec 2007  VOL 147 ISS 24
FILE LAST UPDATED: 2 Dec 2007  (20071202/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> D QUE L16
L5              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation:
Uploading strD.str
```









```
chain nodes :
7  8  9  10  11  12  22  23  24  25  28  29  48
ring nodes :
1  2  3  4  5  6  16  17  18  19  20  21  30  31  32  33  34  35  36  37  38  39
40  41  42  43  44  45  46  47
chain bonds :
1-29  4-28  6-7  7-8  8-16  9-10  11-12  22-23  22-24  22-25  37-48
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  16-17  16-21  17-18  18-19  19-20  20-21  30-31  30-
35
31-32  32-33  33-34  34-35  36-37  36-41  37-38  38-39  39-40  40-41  42-43  42-47
43-44  44-45
45-46  46-47
exact/norm bonds :
1-29  4-28  6-7  7-8  8-16  9-10  11-12  30-31  30-35  31-32  32-33  33-34  34-35
36-37  36-41  37-38  38-39  39-40  40-41  42-43  42-47  43-44  44-45  45-46  46-47
exact bonds :
22-23  22-24  22-25  37-48
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  16-17  16-21  17-18  18-19  19-20  20-21


G1:[*1],[*2]

G2:H,X,[*3]

G3:[*4],[*5],[*6]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
11:CLASS  12:CLASS  16:Atom  17:Atom  18:Atom  19:Atom  20:Atom  21:Atom  22:CLASS
23:CLASS  24:CLASS
25:CLASS  28:CLASS  29:CLASS  30:Atom  31:Atom  32:Atom  33:Atom  34:Atom  35:Atom
36:Atom
37:Atom  38:Atom  39:Atom  40:Atom  41:Atom  42:Atom  43:Atom  44:Atom  45:Atom
46:Atom  47:Atom
48:CLASS



L7            19 SEA FILE=REGISTRY SSS FUL L5
L8             2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L7
L12         1488 SEA FILE=HCAPLUS ABB=ON  PLU=ON  HAGIWARA M?/AU
L13          646 SEA FILE=HCAPLUS ABB=ON  PLU=ON  FUKUHARA T?/AU
L14        22303 SEA FILE=HCAPLUS ABB=ON  PLU=ON  SUZUKI M?/AU
L15          879 SEA FILE=HCAPLUS ABB=ON  PLU=ON  HOSOYA T?/AU
L16            2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L12 OR L13 OR L14 OR L15)
                 AND L8


=> D IBIB ED ABS HITSTR 1-2 L16

L16  ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2006:782685  HCAPLUS  Full-text
DOCUMENT NUMBER:          145:347810
TITLE:                    Utilization of host SR protein kinases and
                          RNA-splicing machinery during viral replication
AUTHOR(S):                Tukuhara, Takeshi; Hosoya, Takamitsu;
                          Shimizu, Saki; Sumi, Kengo; Oshiro, Takako; Yoshinaka,
                          Yoshiyuki; Suzuki, Masaaki; Yamamoto, Naoki;
```

Herzenberg, Leonore A.; Herzenberg, Leonard A.; **Hagiwara, Masatoshi**
CORPORATE SOURCE: Laboratory of Gene Expression, School of Biomedical Science, Tokyo Medical and Dental University, Tokyo, 113-8510, Japan
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2006), 103(30), 11329-11333
CODEN: PNASA6; ISSN: 0027-8424
PUBLISHER: National Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 145:347810
ED Entered STN: 09 Aug 2006
AB Although the viral genome is often quite small, it encodes a broad series of proteins. The virus takes advantage of the host-RNA-processing machinery to provide the alternative splicing capability necessary for the expression of this proteomic diversity. Serine-arginine-rich (SR) proteins and the kinases that activate them are central to this alternative splicing machinery. In studies reported here, the authors use the HIV genome as a model. The authors show that HIV expression decreases overall SR protein/activity. However, the authors also show that HIV expression is significantly increased (20-fold) when one of the SR proteins, SRp75 is phosphorylated by SR protein kinase (SRPK)2. Thus, inhibitors of SRPK2 and perhaps of functionally related kinases, such as SRPK1, could be useful antiviral agents. Here, the authors develop this hypothesis and show that HIV expression down-regulates SR proteins in Flp-In293 cells, resulting in only low-level HIV expression in these cells. However, increasing SRPK2 function up-regulates HIV expression. In addition, the authors introduce SR protein phosphorylation inhibitor 340 (SRPIN340), which preferentially inhibits SRPK1 and SRPK2 and down-regulates SRp75. Although an isonicotinamide compound, SPRIN340 (or its derivs.) remain to be optimized for better specificity and lower cytotoxicity, the authors show here that SRPIN340 suppresses propagation of Sindbis virus in plaque assay and variably suppresses HIV production Thus, the authors show that SRPK, a well known kinase in the cellular RNA-processing machinery, is used by at least some viruses for propagation and hence suggest that SRPIN340 or its derivs. may be useful for curbing viral diseases.
IT **218156-96-8P**
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(utilization of host SR protein kinases and RNA-splicing machinery during viral replication)
RN 218156-96-8 HCAPLUS
CN 4-Pyridinecarboxamide, N-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:612118 HCAPLUS Full-text
DOCUMENT NUMBER: 143:126753
TITLE: Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient
INVENTOR(S): **Hagiwara, Masatoshi; Fukuhara, Takeshi; Suzuki, Masaaki; Hosoya, Takamitsu**
PATENT ASSIGNEE(S): Japan
SOURCE: PCT Int. Appl., 122 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063293	A1	20050714	WO 2004-JP19393	20041224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004308825	A1	20050714	AU 2004-308825	20041224
CA 2551602	A1	20050714	CA 2004-2551602	20041224
EP 1712242	A1	20061018	EP 2004-807749	20041224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1921885	A	20070228	CN 2004-80042165	20041224
IN 2006DN03819	A	20070713	IN 2006-DN3819	20060703
KR 2007017314	A	20070209	KR 2006-714944	20060724
US 2007135367	A1	20070614	US 2007-584482	20070302
PRIORITY APPLN. INFO.:			JP 2003-435085 A	20031226
			WO 2004-JP19393 W	20041224

OTHER SOURCE(S): MARPAT 143:126753
ED Entered STN: 15 Jul 2005
AB It is intended to provide: (1) antiviral agents lowering or inhibiting the activity of an SR protein, more specifically speaking, (i) an antiviral agent promoting the dephosphorylation of an SR protein and (ii) an antiviral agent inhibiting a protein phosphorylating an SR protein; (2) an antiviral agent inhibiting the expression of an SR protein; and (3) an antiviral agent activating a protein having an opposite function to an SR protein. It is also intended to provide compds. which inhibit SRPK phosphorylating an SR protein. These compds. inhibit the activity of the SR protein and show an antiviral effect. Thus, antiviral agents which are efficacious against a novel virus and widely applicable and show a highly sustained effect are provided to cope with the occurrence of various novel viruses.
IT **218156-96-8P 858126-27-9P 858126-30-4P**
858362-05-7P, GIF 0613 **858362-17-1P**, GIF 0616
858362-19-3P, GIF 0341 **858362-21-7P**, GIF 0349
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(method of regulating phosphorylation of sr protein and antiviral agents comprising aniline derivs. as sr protein activity regulators)

RN 218156-96-8 HCAPLUS

CN 4-Pyridinecarboxamide, N-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 858126-27-9 HCAPLUS

CN 4-Pyridinecarboxamide, N-[5-fluoro-2-(1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 858126-30-4 HCAPLUS

CN 4-Pyridinecarboxamide, N-[2-(3,4-dihydro-2(1H)-isoquinolinyl)-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 858362-05-7 HCAPLUS

CN 4-Pyridinecarboxamide, N-[2-[(2S)-2-methyl-1-piperidinyl]-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 858362-17-1 HCAPLUS
CN 4-Pyridinecarbothioamide, N-[2-(1-piperidinyl)-5-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 858362-19-3 HCAPLUS
CN 4-Pyridinecarboxamide, N-[5-chloro-2-(1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 858362-21-7 HCAPLUS
CN 4-Pyridinecarboxamide, N-[2-(1-piperidinyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Structure Search

```
=> FILE HCAPLUS
FILE 'HCAPLUS' ENTERED AT 16:46:55 ON 03 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 3 Dec 2007  VOL 147 ISS 24
FILE LAST UPDATED: 2 Dec 2007  (20071202/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> D QUE L8
L5              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L7           19 SEA FILE=REGISTRY SSS FUL L5
L8            2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L7


=> S L8 NOT L16
L29           0 L8 NOT L16

=> FILE MARPAT
FILE 'MARPAT' ENTERED AT 16:47:11 ON 03 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 147 ISS 22 (20071130/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US   2007249577 25 OCT 2007
DE 102006018869 18 OCT 2007
EP      1845097 17 OCT 2007
JP   2007273900 18 OCT 2007
WO   2007121687 01 NOV 2007
```

GB 2435830 12 SEP 2007
FR 2900050 26 OCT 2007
RU 2307835 10 OCT 2007
CA 2584745 13 OCT 2007

Expanded G-group definition display now available.

=> D QUE L28
L26 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation:
Uploading strF.str



chain nodes :
7 8 9 10 11 12 22 23 24 25 28 29 48
ring nodes :
1 2 3 4 5 6 16 17 18 19 20 21 30 31 32 33 34 35 36 37 38 39
40 41 42 43 44 45 46 47
chain bonds :
1-29 4-28 6-7 7-8 8-16 9-10 11-12 22-23 22-24 22-25 37-48
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21 30-31 30-
35
31-32 32-33 33-34 34-35 36-37 36-41 37-38 38-39 39-40 40-41 42-43 42-47
43-44 44-45
45-46 46-47
exact/norm bonds :
1-29 4-28 6-7 7-8 8-16 9-10 11-12 30-31 30-35 31-32 32-33 33-34 34-35
36-37 36-41 37-38 38-39 39-40 40-41 42-43 42-47 43-44 44-45 45-46 46-47
exact bonds :
22-23 22-24 22-25 37-48
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21

G1:[*1],[*2]

G2:H,X,[*3]

G3:[*4],[*5],[*6]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:CLASS
23:CLASS 24:CLASS
25:CLASS 28:CLASS 29:CLASS 30:Atom 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom
36:Atom
37:Atom 38:Atom 39:Atom 40:Atom 41:Atom 42:Atom 43:Atom 44:Atom 45:Atom
46:Atom 47:Atom
48:CLASS

L28 6 SEA FILE=MARPAT SSS FUL L26

=> DUP REM L29 L28
L29 HAS NO ANSWERS
PROCESSING COMPLETED FOR L29
PROCESSING COMPLETED FOR L28
L30 6 DUP REM L29 L28 (0 DUPLICATES REMOVED)
ANSWERS '1-6' FROM FILE MARPAT

=> D IBIB AB QHIT L30 1-6

L30 ANSWER 1 OF 6 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 144:108321 MARPAT Full-text
TITLE: Preparation of amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
INVENTOR(S): Yang, Lihu; Lin, Songnian; Morriello, Gregori; Guo, Liangqin; Zhou, Changyou
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 141 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006001958	A2	20060105	WO 2005-US17836	20050520
WO 2006001958	A3	20060824		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,

KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AU 2005257859	A1	20060105	AU 2005-257859	20050520
CA 2567851	A1	20060105	CA 2005-2567851	20050520
EP 1753740	A2	20070221	EP 2005-785401	20050520
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1956975	A	20070502	CN 2005-80016231	20050520
IN 2006DN06362	A	20070831	IN 2006-DN6362	20061030
PRIORITY APPLN. INFO.:			US 2004-573625P	20040521
			WO 2005-US17836	20050520

AB Title compds. Q-E-X-G1 (I) and II [Q = piperidinyl, piperazinyl, etc.; E = cyclopentyl, cyclopentenyl, cyclobutyl, etc.; X = 5-7 membered (un)saturated carbocyclic or heterocyclic ring; G1 = ureido, aminosulfonyl, aminocarbonyl, etc.; G2 = single bond, divalent alkyl, aminosulfonyl, etc.; Z = C, N, where no more than two of Z are N; R3-5 = alkyl, OH, alkoxy, etc. when Z = C and absent, or O when Z = N; R2 = R3-5 or is a link to G2; R6 = R3-5 or is a link to any atom on X] are prepared For instance, III is prepared in 5 steps from cyclopentenone, 4-cyanobenzeneboronic acid, 4-phenylpiperidine•HCl and 4-trifluoromethyl-1,2-phenylenediamine. Compds. of the invention bind to the CCR-2 receptor with an IC50 < 1 μM. I are useful for the treatment of inflammatory and immunoregulatory disorders, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis.

MSTR 1



G1 = 6



G2 = (0-2) CH2 (opt. substd.)
G3 = 10



G6 = 50



G24 = bond
G37 = 154

$_{154}^{G38-G41}$

G38 = phenylene
G41 = 162 / 177

$_{162}^{G42-G44}$ $_{177\ 178}^{G48-G51}$

G44 = 173

$_{173}^{G47-G43}$

G47 = C(O)
G48 = 179-154 180-178 / 184-154 185-178

$_{179\ 180}^{G49-G47}$ $_{184\ 185}^{G50-G47}$

G49 = NH (opt. substd.)
G51 = pyridyl (opt. substd.)
Patent location: claim 1
Note: or pharmaceutically acceptable salts or diastereomers
Note: additional ring, oxo, and double bond formation also claimed

L30 ANSWER 2 OF 6 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 143:126753 MARPAT Full-text
TITLE: Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient
INVENTOR(S): Hagiwara, Masatoshi; Fukuhara, Takeshi; Suzuki, Masaaki; Hosoya, Takamitsu
PATENT ASSIGNEE(S): Japan
SOURCE: PCT Int. Appl., 122 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2005063293 A1 20050714 WO 2004-JP19393 20041224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2004308825 A1 20050714 AU 2004-308825 20041224
CA 2551602 A1 20050714 CA 2004-2551602 20041224
EP 1712242 A1 20061018 EP 2004-807749 20041224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
CN 1921885 A 20070228 CN 2004-80042165 20041224
IN 2006DN03819 A 20070713 IN 2006-DN3819 20060703
KR 2007017314 A 20070209 KR 2006-714944 20060724
US 2007135367 A1 20070614 US 2007-584482 20070302
PRIORITY APPLN. INFO.: JP 2003-435085 20031226
WO 2004-JP19393 20041224

AB It is intended to provide: (1) antiviral agents lowering or inhibiting the activity of an SR protein, more specifically speaking, (i) an antiviral agent promoting the dephosphorylation of an SR protein and (ii) an antiviral agent inhibiting a protein phosphorylating an SR protein; (2) an antiviral agent inhibiting the expression of an SR protein; and (3) an antiviral agent activating a protein having an opposite function to an SR protein. It is also intended to provide compds. which inhibit SRPK phosphorylating an SR protein. These compds. inhibit the activity of the SR protein and show an antiviral effect. Thus, antiviral agents which are efficacious against a novel virus and widely applicable and show a highly sustained effect are provided to cope with the occurrence of various novel viruses.

MSTR 1



G2 = NH
G4 = 4-pyridyl
G6 = C(O)
G8 = piperidino
Patent location: claim 16
Note: or pharmaceutically acceptable salts or hydrates

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 3 OF 6 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 143:59808 MARPAT Full-text

TITLE: Carboxamide inhibitors of c-fms kinase for treating inflammation

INVENTOR(S): Player, Mark R.; Baindur, Nand; Brandt, Benjamin; Chadha, Naresh; Patch, Raymond J.; Asgari, Davoud; Georgiadis, Taxiarchis M.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 19 pp., Cont.-in-part of U.S. Ser. No. 831,216.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005131022	A1	20050616	US 2004-970865	20041022
US 2005004112	A1	20050106	US 2004-831216	20040426
AU 2005299476	A1	20060504	AU 2005-299476	20051020
WO 2006047479	A2	20060504	WO 2005-US38307	20051020
WO 2006047479	A3	20070104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1812425	A2	20070801	EP 2005-817168	20051020
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
IN 2007KN01561	A	20070727	IN 2007-KN1561	20070503
PRIORITY APPLN. INFO.:			US 2003-465204P	20030425
			US 2004-831216	20040426
			US 2004-970865	20041022
			WO 2005-US38307	20051020

OTHER SOURCE(S): CASREACT 143:59808

AB Described are carboxamides which inhibit c-fms kinase (no data). The carboxamides may be used for treating inflammation, cancer, cardiovascular disease, etc. Thus, 15 carboxamides, such as 5-cyanofuran-2-carboxylic acid[2-(4-acetylaminopiperidin-1-yl)phenyl]amide, were synthesized.

MSTR 1



G1 = o-C6H4 (opt. substd. by Ph)
G2 = NH
G3 = C(O)
G4 = pyridyl (opt. substd.)
G5 = piperidino (opt. substd.)
Patent location: claim 1
Note: or solvates, hydrates, tautomers or pharmaceutically acceptable salts

L30 ANSWER 4 OF 6 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 141:410819 MARPAT Full-text
TITLE: Preparation of heterocyclic-carboxamide C-fms kinase inhibitors
INVENTOR(S): Player, Mark R.; Baindur, Nand; Brandt, Benjamin M.; Chadha, Naresh; Patch, Raymond J.; Asgari, Davoud; Georgiadis, Taxiarchis
PATENT ASSIGNEE(S): 3-Dimensional Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096795	A2	20041111	WO 2004-US12729	20040426
WO 2004096795	A3	20050310		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2536964	A1	20041111	CA 2004-2536964	20040426
EP 1631560	A2	20060308	EP 2004-750617	20040426
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007525460	T	20070906	JP 2006-513302	20040426
MX 2005PA11503	A	20060531	MX 2005-PA11503	20051025
WO 2007123516	A1	20071101	WO 2006-US14886	20060420
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2003-465204P 20030425

WO 2004-US12729 20040426

OTHER SOURCE(S): CASREACT 141:410819

AB Title compds. I [A = Ph, naphthyl, biphenyl, etc.; R1 = H, aryl, acyl, etc.; X = CO, imino, CS, etc.; R2-3 = H, alkyl, aryl, cycloalkyl, etc.; W = Ph, naphthyl, etc.] are prepared For instance, 5-nitrofuran-2-carboxylic acid N-(2-(piperidin-1-yl)phenyl)amide is prepared from 5-nitrofuran-2- carbonyl chloride and 2-(piperidin-1-yl)aniline. Selected examples have IC50 < 1 μM for C-fms kinase. I are useful for the treatment of glomerulonephritis, rheumatoid arthritis, etc.

MSTR 1

G9—G19

G1 = o-C6H4 (opt. substd. by Ph)
G11 = C(O)
G13 = piperidino
G15 = pyridyl
G19 = 2



Patent location: claim 1
Note: or solvates, hydrates, tautomers or pharmaceutically acceptable salts
Note: also incorporates claims 2 and 3

L30 ANSWER 5 OF 6 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 126:277494 MARPAT Full-text
TITLE: Preparation of piperazinylbenzamides, piperidylbenzamides, and analogs thereof as inflammation and allergy inhibitors
INVENTOR(S): Kawagoe, Keiichi; Shidonii, Kurifuoodo Baafuoodo; Yokohama, Shuichi; Miwa, Tamotsu; Nakajima, Hiroto; Tsukada, Wataru
PATENT ASSIGNEE(S): Daiichi Seiyaku Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 67 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09059236	A	19970304	JP 1995-214431	19950823
PRIORITY APPLN. INFO.:			JP 1995-214431	19950823

AB The title compds. I [R1 = halo, etc.; R2 = halo, nitro, etc.; A = C(:Z)NR3R4 etc.; Z = O, etc.; R3 = (un)substituted aromatic hydrocarbon, etc.; R4 = H, etc.] are prepared N-(4-Chlorophenyl)-3-(4-methyl-1- piperazinyl)-2-nitrobenzamide at 50 mg/kg orally gave 79% inhibition of adjuvant arthritis in rats.

MSTR 1



G1 = phenylene (substd. by (1) G3)
G2 = piperidino (substd. by (1) G14)
G7 = 15-2 16-11



G8 = O
G9 = pyridyl (opt. substd. by (1-3) G22)
G10 = NH
Derivative: or salts
Patent location: claim 1
Note: substitution is restricted

L30 ANSWER 6 OF 6 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 123:339535 MARPAT Full-text
TITLE: Preparation of carbapenem derivatives as antibacterials
INVENTOR(S): Nakagawa, Susumu; Fukatsu, Hiroshi; Ushijima, Ryosuke
PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 256 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9523150	A1	19950831	WO 1995-JP280	19950224
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2184101	A1	19950831	CA 1995-2184101	19950224
CA 2184101	C	20051122		
AU 9518240	A	19950911	AU 1995-18240	19950224
AU 680736	B2	19970807		
EP 747381	A1	19961211	EP 1995-909978	19950224
EP 747381	B1	20011031		
R: AT, BE, DE, DK, FR, GB, IE, IT, LU, MC, NL, PT, SE				
AT 207922	T	20011115	AT 1995-909978	19950224

US 5707987	A	19980113	US 1996-696910	19960823
PRIORITY APPLN. INFO.:			JP 1994-52686	19940225
			JP 1994-64606	19940328
			JP 1994-107568	19940422
			JP 1994-110289	19940426
			JP 1994-114288	19940428
			WO 1995-JP280	19950224

AB The title compds. [I; R1 represents hydrogen or lower alkyl; R2 represents hydrogen or a neg. charge; R3 represents hydrogen or lower alkyl; Ar represents lower alkyl, lower alkylsulfamoyl, etc. (each of which may be substituted by hydroxyl, di(lower alkyl)sulfonyl, etc.), or Ph, naphthyl or a group of formula α or β (each of which may be substituted by hydroxyl, di(lower alkyl)sulfamoyl, etc.), wherein A4 and A5 represent each a single bond, -NHSO2-, etc., and Het represents pyrrolinyl, 1,4-diazabicyclo[2.2.2]octyl, etc. (each of which may be substituted by hydroxyl, carbamoylated lower alkyl, etc.); A1, A2, and A3 represent each a single bond or lower alkylene which may be substituted by lower alkyl, lower alkylsulfamoyl, etc. (each of which may be substituted by hydroxyl, di(lower alkyl)sulfamoyl, etc.) or may be substituted by pyridyl, pyridino, etc. (each of which may be substituted by lower alkyl, carbamoylated lower alkyl, etc.); and W represents sulfur, a single bond, etc.] and their pharmaceutically acceptable salts are prepared Thus, a solution of p-nitrophenyl (1R,5S,6S)-2-diphenoxyphosphoryloxy-6-[(1R)-1- hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylate and (3S,5S)-3-mercapto-1-p-nitrobenzyloxycarbonyl-5-(phenylthiomethyl)- pyrrolidine (preparation given) in MeCN containing diisopropylamide was allowed to react at 50° overnight to give 60% the title compound II (R = p-nitrobenzyloxycarbonyl), which was deprotected to give the monosodium salt of II [R = H]. In an in vitro study, this had an IC50 of 0.39 μg/mL against Staphylococcus aureus.

MSTR 1A



G3 = 54-13 55-16

$_{54}G6—G5_{55}$

G6 = alkylene <containing 1-6 C> (opt. substd. by G7)
G7 = alkylsulfonyl <containing 1-6 C> (opt. substd.) / pyridyl (opt. substd.)
G8 = 106-15 107-17 / 108-15 109-17 / 110-15 112-17

$_{106}G11—G6_{107}$ $_{108}G6—G11_{109}$ $_{110}G6—G11—G6_{112}$

G11 = NH
G12 = 123



G15 = phenylene
G18 = piperidino
Derivative: or pharmaceutically acceptable salts or esters
Patent location: claim 1

Search History

```
L1              STRUCTURE UPLOADED
L2           50 SEA SSS SAM L1

     FILE 'REGISTRY' ENTERED AT 16:14:43 ON 03 DEC 2007
L3              STRUCTURE UPLOADED
L4           50 SEA SSS SAM L3

     FILE 'STNGUIDE' ENTERED AT 16:15:08 ON 03 DEC 2007

     FILE 'REGISTRY' ENTERED AT 16:18:19 ON 03 DEC 2007
L5              STRUCTURE UPLOADED
L6            2 SEA SSS SAM L5
L7           19 SEA SSS FUL L5

     FILE 'HCAPLUS' ENTERED AT 16:24:06 ON 03 DEC 2007
L8            2 SEA ABB=ON  PLU=ON  L7
                E US2007-584482/APPS
L9            1 SEA ABB=ON  PLU=ON  US2007-584482/APPS
                D SCAN
                SEL RN

     FILE 'REGISTRY' ENTERED AT 16:24:45 ON 03 DEC 2007
L10          77 SEA ABB=ON  PLU=ON  (100-07-2/BI OR 109-89-7/BI OR 110-89-4/BI
                OR 110-91-8/BI OR 111-49-9/BI OR 1122-58-3/BI OR 121-17-5/BI
                OR 121-44-8/BI OR 122-04-3/BI OR 123-75-1/BI OR 133184-80-2/BI
                OR 1493-27-2/BI OR 15822-77-2/BI OR 160477-78-1/BI OR 165615-46
                -3/BI OR 1692-79-1/BI OR 175134-94-8/BI OR 20260-53-1/BI OR
                204784-44-1/BI OR 218156-96-8/BI OR 252758-87-5/BI OR 254754-76
                -2/BI OR 3197-42-0/BI OR 32117-01-4/BI OR 333-20-0/BI OR
                33784-44-0/BI OR 364-74-9/BI OR 367-86-2/BI OR 39178-35-3/BI
                OR 39643-31-7/BI OR 40832-82-4/BI OR 412308-45-3/BI OR
                454-79-5/BI OR 494830-83-0/BI OR 496-12-8/BI OR 496-15-1/BI OR
                496012-09-0/BI OR 54231-51-5/BI OR 62054-71-1/BI OR 62054-72-2/
                BI OR 672919-05-0/BI OR 674360-18-0/BI OR 685533-92-0/BI OR
                7087-68-5/BI OR 719-70-0/BI OR 71971-46-5/BI OR 73551-84-5/BI
                OR 784-57-6/BI OR 858126-24-6/BI OR 858126-25-7/BI OR 858126-26
                -8/BI OR 858126-27-9/BI OR 858126-28-0/BI OR 858126-29-1/BI OR
                858126-30-4/BI OR 858362-05-7/BI OR 858362-06-8/BI OR 858362-07
                -9/BI OR 858362-08-0/BI OR 858362-09-1/BI OR 858362-11-5/BI OR
                858362-13-7/BI OR 858362-15-9/BI OR 858362-17-1/BI OR 858362-19
                -3/BI OR 858362-20-6/BI OR 858362-21-7/BI OR 858362-22-8/BI OR
                858362-23-9/BI OR 858362-25-1/BI OR 88-73-3/BI OR 89-61-2/BI
                OR 9013-05-2/BI OR 91-21-4/BI OR 91907-40-3/BI OR 98-16-8/BI
                OR 98-59-9/BI)
L11           7 SEA ABB=ON  PLU=ON  L10 AND L7

     FILE 'HCAPLUS' ENTERED AT 16:25:14 ON 03 DEC 2007
L12        1488 SEA ABB=ON  PLU=ON  HAGIWARA M?/AU
L13         646 SEA ABB=ON  PLU=ON  FUKUHARA T?/AU
L14       22303 SEA ABB=ON  PLU=ON  SUZUKI M?/AU
L15         879 SEA ABB=ON  PLU=ON  HOSOYA T?/AU
L16           2 SEA ABB=ON  PLU=ON  (L12 OR L13 OR L14 OR L15) AND L8

     FILE 'WPIX' ENTERED AT 16:26:38 ON 03 DEC 2007
L17           0 SEA SSS SAM L5
L18           0 SEA SSS FUL L5
```

```
     FILE 'BEILSTEIN' ENTERED AT 16:26:59 ON 03 DEC 2007
L19            0 SEA SSS SAM L5
L20            0 SEA SSS FUL L5

     FILE 'MARPAT' ENTERED AT 16:27:29 ON 03 DEC 2007
L21            1 SEA SSS SAM L5
L22           38 SEA SSS FUL L5
L23            0 SEA ABB=ON  PLU=ON  L22 AND (AY<=2004 OR PY<=2004 OR PRY<=2004)

L24              STRUCTURE UPLOADED
L25            1 SEA SSS SAM L24

     FILE 'STNGUIDE' ENTERED AT 16:39:21 ON 03 DEC 2007

     FILE 'MARPAT' ENTERED AT 16:44:52 ON 03 DEC 2007
L26              STRUCTURE UPLOADED
L27            0 SEA SSS SAM L26
L28            6 SEA SSS FUL L26

     FILE 'HCAPLUS' ENTERED AT 16:46:55 ON 03 DEC 2007
                D QUE L8
L29            0 SEA ABB=ON  PLU=ON  L8 NOT L16

     FILE 'MARPAT' ENTERED AT 16:47:11 ON 03 DEC 2007
                D QUE L28
L30            6 DUP REM L29 L28 (0 DUPLICATES REMOVED)
```